Citi Maintains Buy Rating and $11 PT on Anthera Pharmaceuticals

A report from Citi reiterates its Buy rating and $11 price target on Anthera Pharmaceuticals ANTH. The report states, “This morning Anthera announced positive data from an interim BCell analysis of the PEARL-SC Study. Anthera continues to remain blinded to primary efficacy data. The data indicate that weekly and monthly subQ doses of A-623 (blisibimod) result in statistically significant reductions of B-cells. We view these results as positive, given that the findings are consistent with data from previous clinical studies of A-623.” ANTH closed yesterday at $5.82.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!